$2.21-0.13 (-5.56%)
biote Corp.
biote Corp. in the Healthcare sector is trading at $2.21. Wall Street consensus targets $2.99 (5 analysts), implying a +35.1% move over the next 12 months. The stock is currently 53% below its 52-week high of $4.75, remaining 8.7% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormona...
The latest analyst update for biote keeps the existing price targets unchanged, signaling no revisions to where the stock is currently pegged by coverage. Even without new target moves, the story around biote does not stand still, and investors still have information to track. Ahead, you will see how to monitor shifts in the narrative so you can stay on top of what matters as new data and opinions emerge. Analyst Price Targets don't always capture the full story. Head over to our Company...
Moby summary of biote Corp.'s Q1 2026 earnings call
biote (NASDAQ:BTMD) executives said a voluntary recall of certain bioidentical hormone pellet inventory created a temporary but meaningful headwind in the company’s first quarter of 2026, impacting procedure revenue, margins, and salesforce productivity while management works to restore supply conti
biote Corp. (BTMD) delivered earnings and revenue surprises of -33.33% and -2.71%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Biote’s fair value estimate has been trimmed from US$3.17 to US$2.97 per share, signaling a tighter view on what analysts currently think the stock is worth. That change lines up with recent commentary, where many analysts are lowering price targets into a US$2 to US$3 range while balancing recall related challenges against progress on sales execution and clinic growth efforts. Read on to see how these shifting targets fit into the broader biote story and what to watch as the narrative...